+34 679 490 537info@nanbiosis.com

Blog

Nanbiosis

14 Nov

Drive Pannel Diabetes - Nanbiosis
Diabetes mellitus and pancreatic islet transplant: DRIVE

Today in the World Diabetes Day it is a good moment to remember The Patient Panel of the European project DRIVE- Diabetes Reversing Implants, held in Vitoria (Alava) on June 2 where researches and doctors met with patients and families. The Panel was organized by the NanoBioCel group of CIBER BBN and NANBIOSIS Unit 10 Drug Formulation, with the purpose of letting know the DRIVE project to patients and concect patients with the project scientists and experts in pancreas and stem cell transplantation. Thus, one of the most important health objectives of the European Union was met: to promote direct[...]

19 Jul

Mechanical Characterization of soft biological tissues - Nanbiosis
Mechanical Characterization of soft biological tissues

The experimental study of the mechanical properties of biological tissues is of vital importance. Thorough research into themechanical response of biomaterials is the basis for the creation ofmodels which can accurately reproduce the mechanical behavior ofsuch materials. Adequate mechanical characterization of tissue materials is of paramount interest to the clinical simulations, diagnostic and tissue engineering fields – where the tissue structure, in contrast to classical mechanics application fields, is just simply a biological tissue. In order to obtain their material properties, classical engineering testing techniques have been applied to biologicalmaterials. To reproduce the mechanical behavior of these kinds ofmaterial, many[...]

16 Jan

U12-Nanostructured liquid characterization unit
Characterization of nanomedicines

The quick development of nanotechnology and its application in medicine have generated new alternatives for the diagnosis and treatment of diseases thanks to the novel methods of preparation, modification and characterization of nanomaterials. The knowledge about the behavior of matter at the atomic and molecular level has allowed the creation of tools and processes to observe manipulate and control biological structures on a scale between 100 and 10,000 times smaller than a mammalian cell. Nanomedicine is defined as the application of nanotechnology in view of making a medical diagnosis or treating or preventing diseases. It exploits the improved and often[...]

News about Nanbiosis

29 Nov

New device could monitor treatments with anticoagulant to achive personalized therapies

Researchers from NANBIOSIS units 2 and 4 have designed a biosensor device based on gold nanostructures that precisely detects the presence of the anticoagulant drug from a small blood sample. Treatments with anticoagulants such as Sintrom® (acenocoumarol) face the difficulty of adjusting the drug doses. This device will allow patients to self-regulate the dose.   Researchers of NANBIOSIS unit 4  Biodeposition and Biodetection Unit of the Consejo Superior de Investigaciones Científicas (CSIC), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and CIBER Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) have developed a biosensor device which allows the monitoring of anticoagulants such as Sintrom® (acenocoumarol) to[...]

25 Nov

Bionand, recently incorporated to NANBIOSIS ICTS, among the three national biotechnology reference centers.

The Diario Sur of  Andalucía, publishes today  an article dedicated to BIONAND and its recent accreditation as ICTS by the Ministry of Science, Innovation and Universities, that resolved on November 6 the incorporation of the Nanoimaging Unit of BIONAND to the ICTS NANBIOSIS. In the article, the Director of BIONAND, Jose Becerra Ratia, Professor of Cell Biology of the University of Malaga, explains the opportunities and commitments that imply for the Andalusian Center for Nanomedicine and Biotechnology (BIONAND) its incorporation to NANBIOSIS.[...]

24 Nov

Antimicrobial peptides are a promising kind of molecules to fight multi-drug resistant bacteria

The project titled “Breaking the boundaries of resistance to antimicrobials; searching for new antimicrobials against multiresistant bacteria: work on polycytonic peptides and lipid nanoparticles (BARNAPA)” in which participates Fernando Albericio, Scientific Director of NANBIOSIS unit 3 Synthesis of Peptides Unit, has been selected by La Marató TV3 and finnaced with 383.276,25 €. According to Fernando Albericio, the project arises from the need of effective and safer antibiotics to fight resistant and multi-drug resistant bacteria. In this sens, the proyect developed in collaboration with Miquel Vinyas of the UB and with the Stefania Stefani group of the Universita de Catania  looks at antimicrobia[...]

23 Nov

Two units of NANBIOSIS in the project selected by La Marató TV3 to fight against bacterial infections

La Marató TV3 in its call for biomedical projects in infectious diseases has selected the project “Uses of molecular analysis of Quorum Sensing with the diagnosis of bacterial infections” of the Nb4D group, led by Mª Pilar Marco, Scientific Director of unit 2 of NANBIOSIS and in which Miriam Royo also participates Scientific Coordinator of unit 3 of NANBIOSIS, both in the IQAC-CSIC of Barcelona The project of the Nanobiotechnology for Diagnosis (Nb4D) group of the CSIC and the CIBER-BBN has been selected among more than 200 candidates as a project of scientific excellence to be funded in the ca[...]

22 Nov

Lysosomal Rare Disorders: Focus on Fabry Disease

Last November 19, Vall d’Hebron held a seminar  on Lysosomal Rare Disorders: Focus on Fabry Disease as  part of the Rare Diseases Program at the Vall d’Hebron Campus, in collaboration with the European Commission, the Center for Biomedical Research Network on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and the CIBBIM-Nanomedicine at Vall d Hebron Research Institute (VHIR) through the Smart-4-Fabry projec In the  second plenary session, moderated by Nora Ventosa and Simó Schwartz, Scientific Directors of NANBIOSIS units 6 and 20 and devoted to New therapeutic strategies for lysosomal disorders, the speakers presented their findings regarding biomarkers, genetic variants and treatment protocols.[...]

21 Nov

BIONAND incorporated to the Spanish ICTS Map as a new node of NANBIOSIS

The Scientific, Technological and Innovation Policy Council (CPCTI) of the Spanish Ministry of Science, Innovation and Universities has recently approved the updating of the National ICTS Map (Unique Scientific Technological Infrastructures). ICTS are large installations, resources, facilities and services, unique in its kind, that are dedicated to cutting edge and high-quality research and technological development, as well as to promote exchange, transmission and preservation of knowledge, technology transfer and innovation. After the evaluation by the CPCTI of the ICTS activity during the last four years, NANBIOSIS maintains its presence in the new National ICTS Map, but it introduces a novelty[...]

20 Nov

NANBIOSIS with the research appointment “Towards a New Horizon”

NANBIOSIS has attended today the  10th  Research and Innovation Framework under the slogan “Towards a New Horizon“, organized by the CDTI and the European Commission, in collaboration with the Board of Castilla La Mancha has been held on November 20 in the downtown Congress Center of Toledo “El Greco“. The objective of the Conference has been to review the new developments and analyze the participation of Spain in Horizon 2020 in order to draw conclusions that allow Spanish entities to better face the next calls for proposals. The new proposal of the European Commission (EC) for Horizon Europe has also[...]

19 Nov

EXPLORING COLLABORATIONS BETWEEN ICTS FACILITIES

Members of the NANBIOSIS Coordination Committee have visited the ALBA Synchrotron and its representatives to exchange common research lines, points of view on their complementarity and discuss the collaboration possibilities of the facilities,  both recognized as Unique Scientific Technical Infrastructure  (ICTS) by the Spanish Government. The ALBA Synchrotron consists of a complex of electron accelerators in which the electrons are forced to rotate at a speed of 1 million turns per second. When they are bent, synchrotron light is emitted, allowing to visualize the atomic structure and molecular analysis of materials and study their properties obtaining information that cannot b[...]

16 Nov

NANBIOSIS renews its accreditation as Unique Scientific Technological Infrastructure (ICTS)

NANBIOSIS is one of the 29 ICTS (Unique Scientific Technological Infrastructures) recognized by the Scientific, Technological and Innovation Policy Council (CPCTI) of the Ministry of Science, Innovation and Universities. On November 6, the Council approved the updating of the ICTS Map in which the accreditation of Nanbiosis is renewed as one of them. The new Map is integrated by 29 ICTS, which bring together a total of 62 infrastructures, all of them operative. In the new update the number of ICTS is maintained, but the number of infrastructures is increased by the incorporation of new nodes to existing distributed ICTS.[...]

15 Nov

NANBIOSIS in the Posters presentation in CIBER-BBN ANNUAL CONFERENCE 2018

Last 12 and 13 of November, CIBER-BBN  has celebrated its 12th Annual Conference in Hotel Felipe IV in Valladolid. In poster session participated  NANBIOSIS  itself and some of its units. NANBIOSIS, Infrastructure for the Production & Characterization of Biomaterials, Nanomaterials and medical devices up to preclinical validation. Nanbiosis management team. Divalent cation effects on assembly of histidine-rich protein nanoparticles. López-Laguna, U. Unzueta, O. Conchillo-Solé, A. Sánchez-Chardi, M. Pesarrodona, O. Cano-Garrido, E. Voltà, L. Sánchez-García, N. Serna, P. Saccardo, R. Mangues, A. Villaverde, E. Vázquez (NBT-UAB) (U1 -U18) Antimicrobial peptides (AMPs) anchored on the surface of contact lenses to prevent corneal infections. Emiliano Salvagni, Clara García,[...]

13 Nov

Marisa González, Scientific Director of Unit 16 of NANBIOSIS, candidate to the Rectorate of the University of Extremadura

Marisa González, Scientific Director of NANBIOSIS Unit 16 Surface Characterization and Calorimetry Unit, runs for elections to the Rectorate of the University of Extremadura, to be held on November 27. Marisa González, Professor of Applied Physics in the Faculty of Sciences and the Group Leader of  Microbial Adhesion research group of CIBER-BBN at University of Extremadura, she works with implants and materials on contact with body fluids and tissues, such as blood or bones, and the importance of knowing how these surfaces interact with proteins and molecules in the blood, and how they would do it in case of that bacteria could arrive that[...]

12 Nov

CIBER-BBN Annual Conferences in Valladolid 12-13 November

CIBER-BBN Annual Conferences are taking place now in Hotel Felipe IV in Valladolid, 150 scientists in the field of nanotechnology, biomaterials and bioengineeering gather to share their progress during this year, present their projects and seek synergies for collaboration. The NANBIOSIS Session will take place this afternoon at 16:30, and at 18:30 will take place NANBIOSIS Scientificic Advisory Board meeting                                       &nbs[...]

08 Nov

Update and improvement of unit 20 of NANBIOSIS

NANBIOSIS, U20. In Vivo Experimental Platform, led by Dr. Simó Schwartz and Dr. Ibane Ibasolo, has been recently updated and improved as a result of its participation in the project FICTS1420-20, selected by the MICINN for co-financing by the FEDER Program in ICTS 2014-2020.  These update and improvement include: DLS meassurement system, a fluorimeter and a waterbath for specific activity assays. The fine characterization of the size and size distribution of nanoparticles is essential for the right understanding of their in vivo behavior. The incorporation of this service to the U20 allows the determination of the drug/fluorophore loading/activity of the drug delivery systemistered in vivo, a good quality[...]

07 Nov

Nanomedicine: how to get drugs to the place where they have to act.

At the beginning of June, the Jury of the Rei Jaume I 2018 Awards, formed by Nobel Prize winners, businessmen and scientists, met in Valencia to choose the winners. Today has taken place the ceremony of delivery of the 30th edition of the awards presided over by King Felipe VI. Among the six winners, in the category of New Technologies was Ramón Martínez Mañez, Scientific Director of the CIBER-BBN and Unit 26 of NANBIOSIS. Coinciding with its thirtieth anniversary, the Rei Jaume Foundation has produced a series of videos of interviews with the winners. In this video, Ramón Martínez Mañez,[...]

04 Nov

Preclinical Study for Brain Tumor with Novel Contrast Agents for MRI

Ana Paula Candiota and Carles Arús, Scientific Cordinator and Scientific Director of  U25 of NANBIOSIS, NMR: Biomedical Applications I  have participated in the research published by ACS Applied Materials & Interfaces Journal  that include a preclinical study carried for brain Tumor. Extensive attention has been paid on designing and developing functional imaging contrast agents for providing accurate noninvasive evaluation of pathology in vivo. However, alse-positives or ambiguous imaging and the lack of a robust strategy for simultaneous dual-mode imaging remain to be fully addressed. One effective strategy for improving it is to  design magnetic resonance imaging (MRI) contrast agents (CAs) wit[...]

03 Nov

NANBIOSIS resarchers in CCMIJU identify biomarkers for bridging the gap between preclinical studies in large animal models and clinical trials

Researchers of NANBIOSIS Units at CCMIJU have publish a very relevant article about the studies on  hematological, biochemical and immunological parameters, as well as magnetic resonance derived cardiac function measurements obtained from a swine myocardial infarction model that allows to predict the severity of myocardial infarction in a clinically relevant animal model providing a  simple, affordable and reliable way that could prove useful in the follow up of myocardial infarction and in the evaluation of new therapeutic strategies in this animal model. Biochemical and hematological determinations were performed by the ICTS Nanbiosis (Unit 19. Clinical test lab at CCMIJU). Flow cytometry analyses were performed by the ICTS Nanbiosis[...]

01 Nov

The revolution of nanomedicine by Ramón Martínez Mañez

Ramón Martínez Mañez, Scientific Director of Unit 26 of NANBIOSIS NMR: Biomedical Applications II, will be next Monday, November 5 at 7 pm at the Headquarters of Alicante City (San Fernando, 40), where he will impart the conference “The scientific revolution of Nanomedicine,” The professor of Inorganic Chemistry of the UA and director of the Nanotechnology laboratory, Javier García Martínez, will present the meeting, organized by the Fundación Premios Rey Jaume I and the UA, with the collaboration of the Valencian Agency and Innovation and the Classroom of Science and the Technology of the University of Alicante. Ramón Martínez-Máñez, director of[...]

31 Oct

FUNCATH: Prevention of infectious diseases with functionalized catheters awarded by La Marató de TV3

FUNCATH project,  coordinated by scientists of NANOMOL  group, led by Dr. Imma Ratera, has been awarded by Fundació La Marató de TV3 . NANOMOL is the research group that coordinates NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit, from ICMAB-CSIC and CIBER-BBN. Fundació La Marató de TV3 2017 call was dedicated to infectious diseases and awarded 36 projects among the 186 evaluated according to their excellence, methodology and relevance. FUNCATH is the project for Prevention of infections related to vascular catheters by functionalizing catheters impregnated with thermically activatable hydrogels with broad spectrum antimicrobial agents, whose ultimate goal is the development of vascular catheters coated with multibiofunctiona[...]

24 Oct

NANBIOSIS at the Assembly of Materplat

Next November 14 the General Assembly of Materplat 2018 will take place  in the facilities of the Institute of Ceramics and Glass of the CSIC (ICV-CSIC), on the campus of the Autonomous University of Madrid (Cantoblanco, Madrid). This year, the theme of the Assembly will be focused on how innovation in materials that can be useful in different fields related to smart cities. In this sense, different speakers will show developments in materials very important for sectors such as health, among others. NANBIOSIS will be present through José Becerra, Professor of Cell Biology at the University of Málaga, Scientific Director[...]

15 Oct

NANBIOSIS participation in CPhI Worldwide

NANBIOSIS has participated in the most important event of the pharmaceutical industry, CPhI Worldwide, the largest fair held in Spain. More than 45,000 professionals from more than 150 countries of the main companies in the sector and more than 2,500 companies meet at IFEMA (Madrid) from 9 to 11 October. One of the novelties to be taken into account in this edition of the CPhI Worldwide will be the presentation of biological products by the bioLIVE platform, highlighting the recent growth of biological medicines. BioLIVE, adjacent to CPhI Worldwide in 2018, is the exhibition and conference for large molecule biopharma needs.[...]

11 Oct

Nanoparticles characterization techniques of NANBIOSIS unit 6

The Unit 6 of NANBIOSIS, Biomaterial Processing and Nanostructuring Unit, has organized during the days 8 to 11 of October in the ICMAB-CSIC a course of characterization of Nanoparticles showing some of their techniques to the CSIC researchers. Amable Bernabé, the technician of unit 6 of NANBIOSIS has shown the theory and practice of some methods to characterize nanoparticles and how to handle the necessary equipment. Specifically, these techniques were: Dynamic Light Scattering (DLS) with Zetasizer Nano ZS (Malvern Instruments) Size distribution Z Potential Nanoparticle Tracking Analysis (NTA) with Nanosight NS300 (Malvern Instruments) Size distribution Particle concentration Fluorescence Light Scattering (LS) with Mastersizer 2000 (Malvern[...]

09 Oct

Researchers of NANBIOSIS U9 awarded for a work on scaffolds for dental regeneration

Researchers Manuel Arruebo and Víctor Sebastián, from the CIBER-BBN group led by Jesús Santamaría (NFP) at the University of Zaragoza, that coordinates NANBIOSIS Unit 9 Synthesis of Nanoparticles, have received the second prize of the Resomer Awards granted by the company Evonik, a international recognition to competitiviness. Their work “Promoting bioengineered tooth innervation using nanostructured and hybrid scaffolds”, has been published in the journal Acta Biomaterialia 50 (2017) 493-501. In this work, the researchers of the CIBER-BBN manufactured biodegradable materials such as scaffolds to promote dental regeneration. These scaffolds contained an immunosuppressive drug that, in addition to avoiding rejection after implantation,[...]

05 Oct

Ramón Martínez Máñez Master class on Nanomedicine at the Act of the Academic Opening year 2018-2019  of Spanish university

On September 25, the Polytechnic University of Valencia hosted the Solemn Act of the new Academic Opening year 2018-2019  of Spanish universities, coinciding with the commemoration of its 50th anniversary. This institutional act was chaired by S.M. King Felipe VI, the Minister of Science, Innovation and Universities, Pedro Duque, and the President of the Generalitat Valenciana, Ximo Puig, among many other authorities. Ramón Martínez Máñez, has been in charge of teaching the master class of the new academic year. Ramón Martínez is professor of the Department of Chemistry of the UPV and director of the Interuniversity Research Institute of Molecular[...]

27 Sep

NANBIOSIS participation in BioSpain 2018

NANBIOSIS participates in BioSpain 2018, which is taking place in this ninth edition, in Seville, on September 25-27. BioSpain is one of the main fairs of the European biotechnology sector. It is an event, organized by the Spanish Association of Biocompanies (ASEBIO) in collaboration with  Andalusian government which aims to exchange knowledge, ideas and experiences among all actors in the biotechnology sector. In this edition BioSpain has gathered more than 1,500 attendees, 600 companies and 200 stands. BioSpain is structured in a trade fair, a partnering system that facilitates these meetings, a conference program and an investor’s forum that brings together the most[...]

26 Sep

Nanoparticles in 3D printed bone prostheses that favor regeneration

The research group of Biomaterials for regenerative therapies of CIBER-BBN and IBEC, coordinator of Unit 5 of NANBIOSIS, Rapid Prototyping Unit, led by Elisabeth Engel, expert on nanoparticles and biomaterials, together with the company Avinent, expert in 3D printing, will develop new personalized solutions to improve treatments for bone diseases or injury. So far, they have tested some bioactive nanoparticles based on calcium on the membrane of a chicken embryo and found that blood vessels formed in it and that the cartilage ossified forming a mature bone. The tests were carried out in mice and the result was also positive. The creators[...]

25 Sep

Nanbiosis Contribution to biofilm development

NANBIOSIS Unit 17 Confocal Microscopy Service, has participated in the research results published by Science of the Total Environment  in an article titled “Recycled desalination membranes as support material for biofilm development: A new approach for microcystin removal during water treatment”. The biofilm visualization has been performed by ICTS “NANBIOSIS”  For further information: doi.org/10.1016/j.scitotenv.2018.07.435 &nbs[...]

24 Sep

CIBER-BBN Annual Conference 2018

CIBER-BBN will celebrate its 12th Annual Conference on November 12 and 13 in Vlladolid. In these conference there will be a session dedicated to NANBIOSIS. Likewise, the annual meeting of the Scientific Technical Advisory Committee of NANBIOSIS will take place. As in previous occasions, the meeting will serve to know the activity of NANBIOSIS, the Singular Technical Scientific Infrastructure (ICTS) of the CIBER-BBN and the Minimally Invasive Surgery Center Jesus Usón for the production and characterization of biomaterials, nanomaterials and devices up to its preclinical validation. The new Cutting-edge Biomedical Solutions of NANBIOSIS wiil be presented.[...]

17 Sep

Prof. Jaume Veciana, Scientific Director of NANBIOSIS: Olivier Kahn Plenary Lecture speaker at the ICMM 2018

Prof. Jaume Veciana, Scientific Director of NANBIOSIS has been honored with the Olivier Kahn Plenary Lecture given at the 16th International Conference on Molecule-Based Magnets (ICMM 2018), held on September 1-5, 2018, in Rio de Janeiro, Brazil. For further information: click her[...]

14 Sep

Label-free DNA-methylation detection by direct ds-DNA fragment screening using poly-purine hairpins

Prof Laura Lechuga, Scientific Director of NANBIOSIS Unit 4 Biodeposition and Biodetection Unit, has led the research whose results have been published by Biosensors and Bioelectronics  with the title  “Label-free DNA-methylation detection by direct ds-DNA fragment screening using poly-purine hairpins” Cancer diagnosis continuously evolves due to the better understanding of tumorigenic processes. DNA-methylation is consolidated as an effective biomarker for cancer prognosis and diagnostic even in tumors of unknown origin. The reversibility of this epigenetic mechanism also places it as a high-profile tool for the development of more sophisticated and personalized therapies. Current methodologies, such as bisulfite conversion or PCR amplification, rely on complex[...]

07 Sep

JUMISC OBTAINS TWO INTERNATIONAL RECOGNITIONS AT THE ANNUAL MEETING OF THE LAPAROSCOPIC SURGEONS SOCIETY HELD IN NEW YORK

Dr. Francisco Miguel Sánchez Margallo,  Assistant Director of NANBIOSIS and Scientific Director of JUMISC, has attended the multidisciplinary Congress organized by the Society of Laparoendoscopic Surgeons (SLS), held in New York from August 29 to September 1, where he has presented scientific communications with very innovative results in the specialty of urology. At the annual meeting of this Scientific Society, international specialists related to minimally invasive surgery meet, with the aim of increasing knowledge of laparoscopic, endoscopic and minimally invasive surgical techniques, including robotic surgery. The papers presented by Dr. Francisco M. Sánchez Margallo, have received the Harrith M. Hasson[...]

06 Sep

A new pathway for the prevention of metastasis in colorectal cancer in humans is open: a nanomedicine that selectively eliminates metastatic stem cells

Researchers of NANBIOSIS U18  Nanotoxicology Unit and U1. Protein Production Platform (PPP) at the Biomedical Research Institute of Sant Pau (IIB Sant Pau), of the Hospital of Santa Creu i Sant Pau, of the Universitat Autònoma de Barcelona (UAB), the Superior Council of Scientific Research (CSIC) and the Center for Biomedical Research in Network (CIBER) have published an article in one of the most prestigious international scientific journals in the field of Molecular Medicine, EMBO Molecular Medicine. This article demonstrates the efficacy of the  nanopharmaceutical  that selectively removes metastatic stem cells in animal models of colon cancer. The new drug works like a[...]

05 Sep

NANBIOSIS Unit 27 at VPH2018: VIRTUAL PHYSIOLOGICAL HUMAN 2018

The VPH Conference 2018 is taking place in Zaragoza 5-7 September offering an exciting program of state-of-the art science & engineering in computational (bio)medicine, ranging from foundational research on multiscale modelling of human (patho) physiology, via underpinning research on data science and infrastructures for the virtual physiological human, to clinical applications with participation of NANBIOSIS U27. High Performance Computing Esther Pueyo  is charing the Session 3A: Cardiovascular modeling: from simulation to clinical outcome, Some of the outcomes are presented by Jesús Fernández-Bes: A Bayesian Filtering methodology to identify key drivers of ventricular repolarization variability (Jesus Fernandez-Bes, David Adolfo Sampedro-Puente and Esther Pueyo)  Virtual Physiologica[...]

04 Sep

Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma

As a result of the collaboration carried aout by two units of NANBIOSIS, U4. Biodeposition and Biodetection Unit and U2. Custom Antibody Service (CAbS), it has been developed a compact and simple nanoplasmonic sensing device based on gold nanodisks for the rapid monitoring of acenocoumarol, using highly specific polyclonal antibodies produced against the drug Acenocoumarol (Sintrom®) which implies: A label-free nanoplasmonic device for the rapid monitoring of acenocoumarol in plasmaD. Direct quantification in real time requiring low sample volume is achieved. Non-specific interferences from plasma are minimized using the developed methodology. Excellent accuracy has been observed measuring blind plasma samples. Potential to be implemented as a POC devic[...]

29 Aug

COURSE FOR THE PERFORMANCE OF FUNCTIONS A, B AND C IN RODENTS, LAGOMORFOS, CARNIVORES, PIGS AND SMALL RUMINANTS

On November 2th-30th, Centro de Cirugía de Mínima Invasión Jesús Usón, partner of NANBIOSIS, organizes a theorical and practical course:  “Course for the performance of functions a, b and c in rodents, lagomorfos, carnivores, pigs and small ruminants”. Some researchers of NANBIOSIS Units at JUMISC, will transmit their knowhow and experience to the attendees. The course objetives are to provide adequate training to researchers in the science and welfare of the laboratory animal, as well as the use of bloodless methods of euthanasia that will be carried out with experimental animals in accordance with current legislation and existing recommendations. This course, onc[...]

27 Aug

Recombinant proteins production: optimization strategies.

On October 24th-26th, Aula Científica, in collaboration with IBB, organizes a theorical and practical course on “Recombinant proteins production: optimization strategies“. Some researchers of NANBIOSIS Unit1 Protein Production Platform (PPP), will transmit their knowhow and experience to the attendees, as José Luis Corchero, Rosa Mendoza Moreno and Neus Ferrer Miralles, Scientific Director of the Protein production planform of ICTS NANBIOSIS. The course is aimed at researchers and laboratory technicians from universities, hospitals, companies and research centers who are interested in the expression, production and purification of recombinant proteins with de objectives of analyze and design strategies for the improvement in the expression,[...]

25 Aug

Conversion of Biomolecules into pharmaceuticas Leads using nanovesicles

Nathaly Segovia, Scientific coordinator of NANBIOSIS U 6, Biomaterial Processing and naostructuring unit, explains in this video what the objective of her unit , the services they offer and their technologies  in the field of drug delivery.[...]

24 Aug

Peptides, targeting units and drug conjugates

Miriam Royo, Scientific Coordinator of Unit 3 of NANBIOSIS explains in this video the expertise of the unit in the preparation of difficult peptides (Cyclid and polycyclic peptides, stapled peptides and dificult peptides, depsipetides, natural products and libraries, peptidomimetic libraries, peptides as antigens or adjuvants, tarjeted drug conjugates, etc… as well as therapeutic agen-PEG-targeting unit conjugates[...]

23 Aug

Advanced methods of continuous production of Nanomaterials

Victor Sebastian, researcher of  NANBIOSIS Unit 9 Synthesis of Nanoparticles Unit, explains the production technologies in continuous (Microfluidic systems liquid phase or pyrolysis activated by laser, gas phase in which the nanoparticles are produced)[...]

22 Aug

Micro and nanotechnologies for the release of biotechnological products

José Luis Pedraz, Scientific Director of NANBIOSIS Unit 10, Drug formulation, talks in this video about Micro and polymeric nanoparticles, lipid nanoparticles, non-viral vectors for gene therapy and scaffolds for cell therapy and regenerative medicine and bio 3D printing &nbs[...]

20 Aug

Nanoparticle uptake and in vivo estimates of therapeutic efect and toxicity

Ramón Mangues, Scientific Dierctor of unit 18 of NANBIOSIS, Unit of nanotoxicology, explains in this video some of the animal models used in the unit for preclinical validation of nanoparticles, especially of application in cancer[...]

17 Aug

Biodistribution, safety and efficacy studies of pharmacological release nanotechnological systems

Ibane Abásolo, Scientific Coordinator of NANBIOSIS U20, explains in this video the studies of biodistribution, safety and efficacy of nanotechnological systems of pharmacological liberation that are developed in this unit and , overall, their expertise and differentiation in the sector in the evaluation of nanosystems (with certification ISO 901-2015)[...]

16 Aug

Use of Nanomedicine in preclinical studies and animal models

In this video, Beatriz Moreno Lobato, Head of Unit 19 of NANBIOSIS, Clinical Tests Lab and head of the Animal Modeling Service and Clinical Analysis Laboratory of CCMIJU, gives a talk about the use of Nanomedicine in preclinical studies and animal models. Models of type I and II diabetes, cutaneous ulcer models, animal models in ophthalmology, urology models, cartilage defect models or bone defects models and cardiovascular models such as mycardial infarction in pig that Beatriz explains in more detail, as well as implantation of surgical material in combination with adult stem cells[...]

14 Aug

Testing medical devices and drugs GLP Compliance

En este vídeo Jose Francisco Guillen Caro, Responsable de garantía de calidad del CCMIJU presents the Jesús Usón Minimum Invasion Surgery Center in Cáceres and, especially, the UMISC units that integrate NANBIOSIS, as well as the services and tests they perform, which are certified as GLP[...]

13 Aug

NANBIOSIS develops on demand projects and cutting edge biomedical solutions.

In this video, Jesús Izco Ex. Director of NANBIOSIS, presents NANBIOSIS as one of the 29 ICTS that currently make up the national ICTS map. It consist consists of 27 units grouped into five platforms  which ofer their services under a single contact point and develops on demand projects and cutting edge biomedical solutions in different biomedical applications such as biosensors, live image, contrast agents, therapeutic agents, regenerative medicine, drug delivery, among others.   &nbs[...]

10 Aug

NANBIOSIS Youtube channel: new video-presentations and informative capsules about NANBIOSIS activity

NANBIOSIS makes available its youtube channel with informative videos about the ICTS-NANBIOSIS and the activity of some of its research units and platforms, as well as its Cutting-edge Biomedical Solutions and Nanomedicines Cascade Characterizations NANBIOSIS youtub[...]

09 Aug

Manuel Souto received UAB PhD Extraordinary Award

Jaume Veciana and Imma Ratera (NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit) have supervised Manuel Souto’s PhD thesis entitled “Multifunctional Materials based on TTF-PTM dyads: towards new Molecular Switches, Conductors and Rectifiers”. The School for Doctoral Studies, together with UAB Alumni, organises an event every semester for the award of PhD degrees and PhD special prizes. With 66 PhD programmes, the UAB is one of the leading Catalan universities in the production of theses and generates approximately a third of the doctoral theses that are defended in the Catalan university system each year. The PhD special prizes confer value to theses which have received the qualification of excellenc[...]

08 Aug

Involvement of Cellular Prion Protein in α-Synuclein Transport in Neurons

Researchers of NANBIOSIS U7 Nanotechnology Unit are coauthors of the article “Involvement of Cellular Prion Protein in α-Synuclein Transport in Neurons” by Molecular Neurobiology The cellular prion protein, encoded by the gene Prnp, has been reported to be a receptor of β-amyloid. Their interaction is mandatory for neurotoxic effects of β-amyloid oligomers. In this study, we aimed to explore whether the cellular prion protein participates in the spreading of α-synuclein. Results demonstrate that Prnp expression is not mandatory for α-synuclein spreading. However, although the pathological spreading of α-synuclein can take place in the absence of Prnp, α-synuclein expanded faster in PrPC-overexpressing mice. In addition, α-synuclein[...]

06 Aug

How to optimize strategies to produce recombinant proteins?

Researchers of NANBIOSIS  U1. Protein Production Platform (PPP), organize a course on production of recombinant proteins together with  Aula Científica whose objective is to analyze and design strategies for the improvement in the expression, production and purification of recombinant proteins in heterologous systems. For  further information[...]

03 Aug

Nanopatterns of Surface-Bound EphrinB1 Produce Multivalent Ligand–Receptor Interactions That Tune EphB2 Receptor Clustering

Researchers  of NANBIOSIS U7. Nanotechnology Unit, are coauthors of the article “Nanopatterns of Surface-Bound EphrinB1 Produce Multivalent Ligand–Receptor Interactions That Tune EphB2 Receptor Clustering” published by NanoLetters, ACC Publications. The authors present a nanostructured surface able to produce multivalent interactions between surface-bound ephrinB1 ligands and membrane EphB2 receptors. They have created ephrinB1 nanopatterns of regular size (<30 nm in diameter) by using self-assembled diblock copolymers. Next, they have used a statistically enhanced version of the Number and Brightness technique, which can discriminate—with molecular sensitivity—the oligomeric states of diffusive species to quantitatively track the EphB2 receptor oligomerization process in real time. The results[...]

02 Aug

Science and welfare of the Laboratory animal: New theorical and practical course by JUMISC

From the JUMISC, partner of NANBIOSIS it is been organized: the first edition of the “COURSE FOR THE PERFORMANCE OF FUNCTIONS A, B AND C IN RODENTS, LAGOMORFOS, CARNIVORES, PIGS AND SMALL RUMINANTS”. This course has the following characteristics: • Total duration: 98.5 hours, from November 2 to November 30, 2018, with a semi-face-to-face format and mandatory face-to-face practices on November 26, 27 and 28, 2018. • Cost: € 300 • 25 Places by strict order of registration. The course is already authorized by the Rural Environment Training Service of the Junta de Extremadura. In addition, accreditation has been requested by[...]

01 Aug

The PRO-NANBIOSIS II Network of Excellence begins its execution

The PRONANBIOSIS II Network of Excellence ICTS 2017 SAF2017-90810-REDI, granted by the Spanish Minitry of Science to NANBIOSIS, begins its activity planned for two years. Networks of Excellence favor the development of networks of research groups aimed, in this case, to promote the general coordination of ICTS or Distributed ICTS, as is the case of NANBIOSIS. This Network will give continuity to the previous PRONANBIOSIS Network, which ended on July 31st. The main purposes of the Network are: – to consolidate its unified management model, – to boost its internationalization and strategic positioning – to promote a complete cascade service for nanomaterials[...]

31 Jul

Advanced encapsulation technologies

Researchers of NANBIOSIS  U12. Nanostructured liquid characterization unit, organize a course on advanced encapsulation technologies together with the Consorci Universitat Internacional Menéndez Pelayo Barcelona (CUIMPB) – Center Ernest Lluch whose objective is to provide attendees with the basic concepts about micro and nanoencapsulation techniques,including fundamentals and methods of preparation, as well as new applications in the chemical, cosmetic and pharmaceutical fields, among others. For  further information and program[...]

30 Jul

Artificial 3D Culture Systems for T Cell Expansion

Scientists of NANBIOSIS U6. Biomaterial Processing and Nanostructuring Unit, have recently pubished an article  in the ACS Omega  about the design 0f 3D platforms specific for T cell culture to improve the current T cell  expansion systems to introduce new in vitro models and facilitate the broad use of ACT in the clinics. Adoptive cell therapy, i.e., the extraction, manipulation, and administration of ex vivo generated autologous T cells to patients, is an emerging alternative to regular procedures in cancer treatment. Nevertheless, these personalized treatments require laborious and expensive laboratory procedures that should be alleviated to enable their incorporation into the clinics. With the objectiv[...]

27 Jul

Nano-carrier to release drugs into damaged cells

Senescent cells are damaged cells that do not perform their normal roles anymore but that are not dead –hence they are commonly known as zombi cells. These cells interfere with the functioning of the tissue in which they accumulate. Senescence is a cell program that is triggered by many types of damage and senescent cells are present in many diseases. They accumulate in diverse types of tissues during aging, thus contributing to the progressive deterioration associated to aging. Eliminating these zombi cells is one of the challenges facing science today. In the Cellular Plasticity and Disease lab headed by the ICREA researcher Manuel Serrano at[...]

26 Jul

Strong Ministerial Support to NANBIOSIS ICTS

Spanish Goverment  has granted a “Network of Excellence”: ICTS 2017 SAF2017-90810-REDI”, with the maximum funding of 89,700 euro to consolidate the unified management model of NANBIOSIS, to boost its internationalization and strategic positioning as well as to promote a complete cascade service for nanomaterials characterization. The two years lasting project has been granted within the frame of the National Programme for Fostering Excellence in Scientific and Technical Research. This Excellence project, funded by the Spanish Ministry of Economy and Competitiveness, will consolidate and promote the One Stop Shop model of NANBIOSIS, which facilitate to public and private centers of research and companies[...]

25 Jul

Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications

Scientists of Unit 8 of NANBIOSIS are co-authors of the article “Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications“, recently published  by Biotechnology and Bioengineering.  The fabrication of Exoliver was performed by the platform of Production of Biomaterials and Biomolecules of the ICTS, more specifically by the “NANBIOSIS,” Unit 8. Maintenance of the complex phenotype of primary hepatocytes in vitro represents a limitation for developing liver support systems and reliable tools for biomedical research and drug screening. We herein aimed at developing a biosystem able to preserve human and rodent hepatocytes phenotype in vitro based on t[...]

24 Jul

The general consul of France meets with NANBIOSIS researchers

The general consul of France in Barcelona, ​​Mr. Cyril Piquemal visited the IBB UAB facilities last July 18, to find out about the research that is being carried out and, in particular, explore possible collaborations in nano-pharmacy development projects. During the visit, the Consul of France in Barcelona was received by Màrius Martínez, Vice President of International Relations at the UAB; Maite Paramio, Deputy Vice President; Ivan Martínez, vice president of Research; Salvador Ventura, director of the Institute of Biotechnology and Biomedicine, and Antonio Villaverde, head of the IBB Nanotechnology Unit-NANBIOSIS  U1. Protein Production Platform (PPP) Next, the mayor visited[...]

23 Jul

Interferometric nanoimmunosensor for label-free and real-time monitoring of Irgarol 1051 in seawater

As a result of a collaboration in the context of the EC-FP7 program OCEAN 2013, NANBIOSIS Unit 2 Custom Antibody Service (CAbS) and  Unit 4. Biodeposition and Biodetection,  the research groups coordinating this NANBIOSIS Units have recently published an article titled “Interferometric nanoimmunosensor for label-free and real-time monitoring of Irgarol 1051 in seawater” in the scientific magzine  iosensors and Bioelectronics. The CIBER-BBN-ICN2 group  Nanobiosensors and Bioanalytical Applications, led by Prof. Laura Lechuga has developed the immunosensor that is described in the article using immunoreactive, produced in the group of  Nanobiotechnology for Diagnostics Group (Nb4D), led by Prof. Pilar Marco, with the collaboration of CAbS,[...]

22 Jul

Nanomedicine to fight against the spread of cancer

Nanoligent, S.L., the company stablished on March 2017 by professors Dr. A. Villaverde and Dra. E. Vázquez from NANBIOSIS Unit 1, professor Dr. M. Mangués from NANBIOSIS Unit 18, and entrepreneur Dr. M. Rodríguez is highlighted in la Vanguardia. More information here &nbs[...]

18 Jul

Seminal plasma influences the fertilizing potential of cryopreserved stallion sperm

Beatriz Macías García, researcher at  NANBIOSIS U23. Assisted Reproduction,  is co-author of the article “Seminal plasma influences the fertilizing potential of cryopreserved stallion sperm”, publish by the Journal Theriogenology.   Seminal plasma (SP) contains proteins that may influence cryosurvival and prevent capacitation-like changes due to freezing and thawing. The objective of this study was to investigate the effect of adding pooled SP from “good” (GF) or “bad” (BF) freezer stallions on sperm cells’ fertilizing ability. “Good freezers” refers to stallions that usually produce ejaculates which can withstand cryopreservation, whilst “bad freezer” stallions produce ejaculates which cannot tolerate the freezing process. A heterologous zona binding assay with in vitro matured[...]

17 Jul

NANBIOSIS researcher Iñaki Ochoa, interviewed in the Heraldo de Aragón criticizes the administrative obstacles to science imposed by law.

Scientists of NANBIOSIS in the University of Zaragoza participated in the assembly held las week that put on the table the risks of applying rules in an incoherent way and without taking into account the reality of the work that researchers develop. The Spanish public contrat law prevents the University to spend more than 15,000 euros per provider per year, which complicates the purchases of material. The scientists ask that this legislation not be applied More than three hundred researchers  have signed a manifesto in which they denounce that some provisions of the new Spanish law on public contracts prevent them[...]

16 Jul

Gold/Silver/Gold Trilayer Films On Nanostructured Polycarbonate Substrates For Direct And Label‐Free Nanoplasmonic Biosensing

Laura Lechuga, Scientific Director of NANBIOSIS U4. Biodeposition and Biodetection Unit is coathor of the article “Gold/Silver/Gold Trilayer Films On Nanostructured Polycarbonate Substrates For Direct And Label‐Free Nanoplasmonic Biosensing” published by Ultrasmooth gold/silver/gold trilayer nanostructured plasmonic sensors were obtained using commercial Blu-ray optical discs as nanoslits-based flexible polymer substrates. A thin gold film was used as an adhesion and nucleation layer to improve the chemical stability and reduce the surface roughness of the overlying silver film, without increasing ohmic plasmon losses. The structures were physically and optically characterized and compared with nanostructures of single gold layer. Ultrasmooth and chemically stable trilayer nanostructures with a surface roughness <0.5 nm[...]

15 Jul

Mimicking physiological O2 tension in the female reproductive tract improves assisted reproduction outcomes in pig

Francisco M. Sánchez-Margallo, Assistant Director of NANBIOSIS and Scientific Coordinator o NANBIOSIS U23. Assisted Reproduction,  is co-author of the article “Mimicking physiological O2 tension in the female reproductive tract improves assisted reproduction outcomes in pig”, publish by the Journal Molecular human reproduction The research has been carried out with the participation of the NANBIOSIS  Assisted Reproduction Lab that has  a 120 m2 laboratory, small animal surgery, clinical analysis support, etc. and it is featured with two intracitoplasmatic micromanipulation equipment of the latest generation with IMSI, Laser and Oosight system, embryo biopsy systems, vision systems of the mitotic spindle, with flow cabinets with stereo-microscopes and heated plates, incubators[...]

13 Jul

Manuel Doblaré, Unit 13 of NANBIOSIS, SEMNI Award O. C. Zienkiewicz

The Spanish Society of Numerical Methods in Engineering (SEMNI) has awarded the SEMNI O. C. Zienkiewicz prize to Professor Dr. Manuel Doblaré. The SEMNI O. C. Zienkiewicz Award is the highest award given by this company and recognizes, in this case, both the undisputed scientific curriculum of prof. Doblaré as his permanent contribution to the good functioning of this society, of which he has been a founding member and member of its executive committee until 2007, having also organized the Congress of Numerical Methods in Zaragoza in 1996. The prize will be given during the Congress of Numerical Methods to[...]

12 Jul

JUMISC, partner of NANBIOSIS has hosted PICCOLO Project Face-to-Face Meeting.

During two days meeting, the PICCOLO consortium 4th face to face meeting has taken place. Project partners reviewed the current state of the development, results, deliverables and future actions. Inspired in the experimental setting up of the JUMISC, one of the most interesting topics in this meeting was the pre-clinical discussion about the validation plan of the PICCOLO prototypes. The PICCOLO consortium analysed both laboratory and pre-clinical trials that will start at the end of this year. Some detailed protocols and preliminary results of the experimental models for these trials were presented as results of a close collaboration between clinical and technological partners. It has been a great[...]

11 Jul

Jesús Santamaría, interviewed in the Cadena Ser Radio, denounces the bureaucratic barriers that hinder research.

Jesús Santamaría, Scientific Director of NANBIOSIS Unit 9, Synthesis of Nanoparticles Unit, denounces the bureaucratic obstacles of the Law of Contracts, which are paralyzing the investigations whenever it is necessary to buy material or hire personnel.  His research against cancer, which received one of the most powerful European funding of more than two million euros, is stranded because of this rule, which requires to take out any purchase over 15,000 euros. “You can not do research like that,” Santamaría said. “In other countries there are no obstacles and we have to compete with them” With the entry into force on March 9 of[...]

10 Jul

Biomaterials as signal-releasing platforms

Scientists of the CIBER-BBN and IBEC reserch group Biomaterials for Regenerative Therapies, led by Miguel Angel Mateos-Timoneda and Elisabeth Engel who run NANBIOSIS U5. Rapid Prototyping Unit,  have  published a review of the state-of-the-art in biomaterials for skin healing that proposes a move towards more personalized, in situ therapies. Skin wound healing repairs and restore tissue through a complex process that involves different cells and signalling molecules that regulate cellular response and the remodelling of the extracellular matrix. Publishing in Advanced Drug Delivery Reviews, the article begins by summarizing recent advances in therapies for healing that combine biomolecule signals such as growth factors and cytokines wit[...]

09 Jul

NANBIOSIS Unit 14 of Cell Therapy receives the Research Excellence Accreditation

Dr. Javier García Casado, Scientific Director of NANBIOSIS Unit 14, of Cell Therapy, has been awarded  by the General Secretariat of Science, Technology and Innovation, belonging to the Ministry of Economy and Infrastructure of the Autonomous Community of Extremadura, the accreditation of research excellence of the Autonomous Community of Extremadura in the field of Life Sciences, which includes the research areas of Cellular and Molecular Biology, Medical Sciences, Pharmacology and Physiology, Food Science and Technology and other related fields. The accreditation, which is valid for 4 years, is the recognition of Javier García Casado’s research career, highlighted by his contributions[...]

08 Jul

New cover ACS Sustainable Che. Eng. by Scientists of NANBOSIS U9

Scientists of NANBIOSIS Unit 9 Synthesis of Nanoparticles Unit are coauthors of  of the New cover ACS Sustainable Chem. Eng. Sustainable Production of Drug-Loaded Particles by Membrane Emulsification. Albisa A, Piacentini E, Arruebo M, Sebastian V, Giorno L. ACS Sustainable Chem. Eng., 2018, 6 (5), pp 6663–6674 March 13, 2018. DOI: 10.1021/acssuschemeng.8b00401. IF: 5,951[...]

07 Jul

Stimuli-Responsive Functionalization Strategies to Spatially and Temporally Control Surface Properties: Michael vs Diels–Alder Type Additions

NANBIOSIS Unit 6 Biomaterial Processing and Nanostructuring and Unit 3 Synthesis of Peptides collaborate in a research whose results are published by The Journal of Physical Chemistry B Stimuli-Responsive Functionalization Strategies to Spatially and Temporally Control Surface Properties: Michael vs Diels–Alder Type Additions Adriana R. Kyvik, Carlos Luque-Corredera, Daniel Pulido, Miriam Royo, Jaume Veciana, Judith Guasch, and Imma Ratera The Journal of Physical Chemistry B 2018 122 (16), 4481-4490 DOI: 10.1021/acs.jpcb.8b01652 Stimuli-responsive self-assembled monolayers (SAMs) are used to confer switchable physical, chemical, or biological properties to surfaces through the application of external stimuli. To obtain spatially and temporally tunable surfaces, we present microcontact printed SAMs of a hydroquinone molecule that are used[...]

06 Jul

Josep Samitier, Scientific Director of NANBIOSIS Unit 7, Panelist in a round table about the current situation of biomedical research

Last month NANBIOSIS Unit 7 Nanotechnology Unit Scientific Director Josep Samitier was one of the panelists in a round table organised by the Cercle de Salut, an association devoted to improving the health system so that it may respond adequately to the challenges posed by society. In the discussion at the Parc de Recerca Biomèdica de Barcelona (PRBB) entitled ‘L’excel·lència en la recerca, reptes immediats’, Josep and the other participants – ISGlobal director Antoni Plasencia and IrsiCaixa director Bonaventura Clotet – discussed the current situation of biomedical research in Catalonia. In particular, the hot topic under discussion was the impact that recent[...]

05 Jul

Judith Guasch, (NANBIOSIS Unit 6) has been granted with a Ramon y Cajal grant from the Spanish Goverment

Judith Guasch holds a senior postdoctoral research position at the NANOMOL group CIBER-BBN at  ICMAB-CSIC that coordinates NANBIOSIS Unit 6 Biomaterial Processing and Nanostructuring Unit, after being awarded with a TecnioSpring fellowship  (Marie Curie Fellow, Cofund – Catalan Government and EU). Since 2017 she is also head of a Max Planck Partner Group (Dynamic Biomimetics for Cancer Immunotherapy) in collaboration with the Max Planck Institute for Medical Research (Heidelberg, Germany). Judith’s research interests are focused on the design, synthesis, and fabrication of multifunctional molecular and supramolecular materials for biomedical applications. Special interest is devoted to study the cell-material interaction for improving novel adoptive cell therapies for the treatment of cancer.[...]

04 Jul

«The combination of nanotechnology with bioengineering and biomedicine allows us to act on the human body on a molecular scale»

Josep Samitier, Scientific Director of NANBIOSIS Unit 7 Nanotechnology Unit, has been highlighted in ‘Dominical’ supplement of the Diari de Girona last week. More information here [...]

03 Jul

Parasympathetic tone activity evaluation to discriminate ketorolac and ketorolac/tramadol analgesia level in swine

Francisco M. Sánchez-Margallo, Assistant Director of NANBIOSIS and Scientific Director of JUMISC is co-author of the article “Parasympathetic tone activity evaluation to discriminate ketorolac and ketorolac/tramadol analgesia level in swine”, publish by  Anesth Analg. 2018 Jun 14. doi: 10.1213/ANE.0000000000003573. [Epub ahead of print] Abstract BACKGROUND: Evaluation of nociceptive–antinociceptive balance during general anesthesia is still challenging and routinely based on clinical criteria. Analgesic drug delivered may be optimized with parasympathetic tone activity (PTA) monitor. This study compares ketorolac and ketorolac/tramadol balance analgesia using a PTA monitor. METHODS: Pain intensity response was assessed using a 0–100 numerical state scale (PTA) after nociceptive stimuli in pigs under stab[...]

02 Jul

Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin

Researchers of NANBIOSIS Unit 1 and NANBIOSIS Unit 18, led by Prof Antoni Villaverde have published the article “Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin” at SMALL journal. Under the unmet need of efficient tumor‐targeting drugs for oncology, a recombinant version of the plant toxin ricin (the modular protein T22‐mRTA‐H6) is engineered to self‐assemble as protein‐only, CXCR4‐targeted nanoparticles. The soluble version of the construct self‐organizes as regular 11 nm planar entities that are highly cytotoxic in cultured CXCR4+ cancer cells upon short time exposure, with a determined IC50 in the nanomolar order of magnitude. T[...]

01 Jul

Prof. Laura Lehuga, new Associate Editor at Analyst Editorial Board

Laura Lechuga, Scientific Director of NANBIOSIS Unit 4 Biodeposition and Biodetection Unit, at Catalan Institute of Nanoscience and Nanotechnology,  has joined the Analyst Editorial Board as an Associate Editor from today. Analyst publishes analytical and bioanalytical research that reports premier fundamental discoveries and inventions and the applications of those discoveries, unconfined by traditional discipline barriers Laura Lechuga is the CSIC Research Professor at the Catalan Institute of Nanoscience and Nanotechnology, Spain. She is the leader of the CIBER-BBN-ICN2 Nanobiosensors and Bioanalytical Applications Group, which focusses on the technological development of nanophotonic biosensors, their integration into portable lab-on-a-chip platforms and their application in clinical and environmental diagnostics. Professor Lechuga[...]

30 Jun

Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs

Scientists of NANBIOSIS  Units U1. Protein Production Platform (PPP),  and U18. Nanotoxicology Unit, have recently published an article titlled “Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs” in the Journal of  Controlled Release. Loading capacity and drug leakage from vehicles during circulation in blood is a major concern when developing nanoparticle-based cell-targeted cytotoxics. To circumvent this potential issue it would be convenient the engineering of drugs as self-delivered nanoscale entities, devoid of any heterologous carriers. In this context, we have here engineered potent protein toxins, namely segments of the diphtheria toxin and the Pseudomonas aeruginosa exotoxin as self-assembling, self-delivered therapeutic materials targeted to CXCR4+ cancer stem cells. The systemic administration of both nanostructured drugs in a[...]

29 Jun

Graphene 2018 with the participation of NANBIOSIS Unit 8

Eli Prats  and Eduard Masvidal researchers of NANBIOSIS Unit 8 Micro and Nanotechnology Unit have shown their last results in ECoG recordings and biosensing using graphene based devices at the 8th edition of Graphene Conference series, the largest European Event in Graphene and 2D Materials, which is taken place in Dresden (Germany) from the 26th until the 29th of June 2018. Eli Prats has spoken on Label-free Direct Detection of Thrombin through graphene SGFET with chemically modified aptamers and Eduard Masvidal has given a talk on Graphene transistors for ultra-slow frequency (< 0.1Hz) in vivo neural recordings showing graphene SGFETs as[...]

28 Jun

Release of targeted protein nanoparticles from functional bacterial amyloids: A death star-like approach

Sustained release of drug delivery systems (DDS) has the capacity to increase cancer treatment efficiency in terms of drug dosage reduction and subsequent decrease of deleterious side effects. In this regard, many biomaterials are being investigated but none offers morphometric and functional plasticity and versatility comparable to protein-based nanoparticles (pNPs). Researchers of NANBIOSIS units 1 and 18 are co-authors of an article  publish by Journal of Controlled Release in which it is described a new DDS by which pNPs are fabricated as bacterial inclusion bodies (IB), that can be easily isolated, subcutaneously injected and used as reservoirs for the sustained release of targeted pNPs. Our approach combines t[...]

27 Jun

Online oxygen monitoring using integrated inkjetprinted sensors in a liver-on-a-chip system

Scientists of NANBIOSIS Unit 8. Micro – Nano Technology Unit, led by Gemma Gabriel, Scientific Coordinator of the Unit, are the authors of the article “Online oxygen monitoring using integrated inkjetprinted sensors in a liver-on-a-chip system”, published by Lab on a chip. The demand for real-time monitoring of cell functions and cell conditions has dramatically increased with the emergence of organ-on-a-chip (OOC) systems. However, the incorporation of co-cultures and microfluidic channels in OOC systems increases their biological complexity and therefore makes the analysis and monitoring of analytical parameters inside the device more difficult. In this work, theauthors present an approac[...]

26 Jun

Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides

Scientists of Units 1 and 18 of NANBIOSIS are coathors of the article  “Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides” published by Nanomedicine: Nanotechnology, Biology and Medicine Arginine-rich protein motifs have been described as potent cell-penetrating peptides (CPPs) but also as rather specific ligands of the cell surface chemokine receptor CXCR4, involved in the infection by the human immunodeficiency virus (HIV). Polyarginines are commonly used to functionalize nanoscale vehicles for gene therapy and drug delivery, aimed to enhance cell penetrability of the therapeutic cargo. However, under which conditions these peptides do act as either unspecific or specific ligands is unknown. The authors have here explored the cell penetrability[...]

26 Jun

Nanoligent obtains the first prize in the Tech Transfer Competition in the ONCO Emergence forum

Last June 21-22th, took place at the Fira Gran Via in Barcelona, the ONCO Emergence forum, a networking conference focused on setting up transnational collaboration projects in oncology by promoting interaction among research institutes, companies and medical facilities like hospitals. In other to promote alliances and generate collaborative projects from hospitals and academia to other stakeholders, ONCO Emergence Forum Barcelona has created a  Tech Transfer Competition that features cherry-picked entrepreneurs, TTO or principal investigators developing new technology ready to be licensed or in development through a spin-off.  Selected participants presented their innovative projects in a 6-minute English pitch to an experienced[...]

26 Jun

Esther Pueyo, NANBIOSIS U 27, at the 3rd Barcelona VPH Summer School

The 3rd VPH Summer School was held in Barcelona, ​​on June 18-22, 2018.  The VPH Summer School series is co-organized by the Barcelona MedTEch – Pompeu Fabra University and by the Virtual Physiological Human Institute. The Summer School provides a thorough overview and hands-on experience in state-of-the-art Virtual Physiological Human (VPH) research. The event is dedicated to PhD students and junior postdocs who seeks cross dissemination and a guided experience through the use of computer models and simulations to tackle specific clinical problems, not only engineers but also biomedical scientists and medical doctors with an interest in computer modeling and[...]

25 Jun

Nanoligent, the spin off created by the Directors of Units 1 and 18 of NANBIOSIS, awarded for the best company in Health Sciences given by the law firm RCD

NANOLIGENT is awarded for the best company in Health Sciences  Price given by the law firm RCD. The XXIII Investment Forum of ACCIÓ 2018 was celebrated last June 20th  with the aim of connecting with the world of private investment.  ACCIÓ, Company Competitiveness Agency, had previously published a catalog of startups with the most potential startups in Catalonia, projects selected from more than 100 candidatures were presented for the 2018 Investment Forum of ACTION. The 50 companies in this catalog stand out due to their differential nature and innovative value, due to their social impact and the involvement of the entrepreneuria[...]

25 Jun

A CO2 optical sensor based on self-assembled metal–organic framework nanoparticles

Carbon dioxide (CO2) is a known pollutant that affects the performance of humans in workplaces, schools and other indoor areas. Thus, the development of devices for sensing and monitoring CO2 levels is crucial for many fields such as food packaging and for human safety indoors. Researchers of NANBIOSIS U4. Biodeposition and Biodetection Unit, led by Prof. Laura M. Lechuga, are co-authors of the article “A CO2 optical sensor based on self-assembled metal–organic framework nanoparticles published  by Journal of Materials Chemistry A., wich  shows  an optical CO2 sensor fabricated by integration of a metal–organic framework (MOF) onto bimodal optical waveguides. The sensor showed a broad linear[...]

22 Jun

NANOMEDICINE APPLICATIONS IN DRUG DELIVERY AND TARGETING: NANBIOSIS – NANOMED Industrial Forum

Yesterday took place in Barcelona, at Barcelona School of Management, Universitat Pompeu Fabra, a meeting of resarch groups and units of NANBIOSIS and CIBER-BBN and companies in the third B2B Forum organized by NANBIOSIS, in this case together with NANOMED SPAIN. Thirteen companies and twelve groups from CIBER-BBN and CCMIJU (ten of them coordinating NANBIOSIS units) got together to explain, through short presentations of ten minutes, those lines of their work aimed at finding synergies and potential collaborations in the area of Nanomedicine apllications in drug delivery and targeting. There was also a talk by a  representative of CDTI (Spanis[...]

21 Jun

Infections such as Candiasis will be detected in 30 minutes

Ramón Martínez Máñez, Elena Aznar and Ángela Ribes, researchers of Unit 26 of NANBIOSIS, NMR: Biomedical Applications II, in collaboration with researchers from the Universitat Politècnica de València, with the Universitari i Politècnic La Fe Hospital and the Rovira i Virgili University, have developed a new material that allows to detect quickly and with a high sensitivity infections caused by Candida albicans, a type of fungus that can be found in different biological fluids, causing opportunistic infections such as Candidemia or Invasive Candidiasis. According to Javier Pemán, head of section and head of the Mycology Unit of the Microbiology Service of[...]

20 Jun

NANBIOSIS working on the development of next generation catheters

NANBIOSIS’ partners CIBER-BBN and JUMISC, with another 44 European partners, led by Philips Electronics Nederland B.V, will work on the development of next genration catheters.  The project, Position-II  (Ref. n. 783132), that pretends to diversify the production of smart catheters (overcoming the obsolescence of current ones), improve their performance (facilitating their use to be smaller), reduce current production costs and break existing monopolies, has been submitted to the Call for Electronic Components and Systems for European Leadership (ECSEL)- Horizon 2020, with a duration of three years -starting on 1/6/18- and with a budget of over €41M, (€10.4M-financed by European Union) T[...]

19 Jun

Institutional impulse to accelerate 3D printing projects

Elisabeth Engel,  Scientific Director of Unit 5 of NANBIOSIS, U5. Rapid Prototyping Unit, will led the research project, QuirofAM, to produce biodegradable and bioactive scaffolds printed in 3D as osteochondral and maxillofacial substitutes. This is one of the projects to be promoted by LLAVOR 3D Community, an association of Catalan entities, created last month, which includes the IBEC (housing units 5 and 7 of NANBIOSIS). LLAVOR 3D Community aims to accelerate the development and adoption of additive manufacturing and 3D printing technologies by the industry. Within the projects of the LLAVOR 3D Community, new software tools, new materials, more efficient and versatile production[...]

18 Jun

Intestinal histopathological changes in a porcine model of pneumoperitoneum-induced intra-abdominal hypertension

Francisco Miguel Sánchez Margallo, Scientific Director of  JUMISC, is co-author of the publication “Intestinal histopathological changes in a porcine model of pneumoperitoneum-induced intra-abdominal hypertension” by Surgical Endoscopy. The study was performed with the participation of NANBIOSIS Units: U21-Experimental operating rooms, and U22-Animal housing. and showed that the  evolution of intestinal injuries from pneumoperitoneum-induced IAH depends on the degree of IAP, these damages may be associated with decreases in APP and pHi, and increases in Lc For further information: click her[...]

17 Jun

Why research in micro-electronics? Neural interfaces, interaction between the nervous and the artificial system

Dra. Rosa Villa,  Scientific Director of NANBIOSIS U8. Micro – Nano Technology Unit, explained last June, 11 at the Residence of Researchers of Barcelona the great scientific challenges in finding tools that allow a good interaction between the nervous and the artificial system. This talk is part of the series of conferences organized by the CNM with the theme “Why research in micro-electronics?” Dr. Manuel Lozano, Director of the CNM, introduced the talk explaining that with microelectronic technology scientists  can capture the signals that occur in the nerves and in the brain and presented Rosa Villa  as a doctor  with a PhD in[...]

16 Jun

Interpretation of motion analysis of laparoscopic instruments based on principal component analysis in box trainer settings

Francisco Miguel Sánchez Margallo, Scientific Director of  CCMIJU and NANBIOSIS U21. Experimental operating rooms, is co-author of the publication “Interpretation of motion analysis of laparoscopic instruments based on principal component analysis in box trainer settings” published by Surgical Endoscopy The study results show that three new HSMAPs per hand were defined for PG and PC tasks, and two per hand for KS task. PG presented validity for HSMAPs related to insecurity and economy of space. PC showed validity for HSMAPs related to cutting efficacy, peripheral unawareness, and confidence. Finally, KS presented validity for HSMAPs related with economy of space and knotting securitya. Thus,[...]

15 Jun

Liquid nitrogen tank
NANBIOSIS U2 incorporates a new Nitrogen tank to store cells

NANBIOSIS U2. Custom Antibody Service (CAbS), is incorporating new equipment as a result of its participation in the project FICTS1420-27, selected by the MINECO for co-financing by the FEDER Program in ICTS 2014-2020. Recently the purchase and installation and set-up of a new nitrogen tank to store cells has taken place. The storage of cell lines of monoclonal antibody-producing hybridomas is a process in which the cells are conserved when they are cooled to temperatures typically at -196 ° C in liquid Nitrogen tanks. With temperatures below -130 ° C the activity Biological ceases and storage at these temperatures is vital to keep the materia[...]

14 Jun

Graphene will be manufactured with greater economic and biomedical benefits at NANBIOSIS unit 8

The unit 8 of NANBIOSIS U8-Micro, nanotechnology, will offer HIGH-QUALITY GRAPHENE GROWN ON ONE-layer or multi-layer CU SHEETS, as well as graphene transferred to different rigid and flexible parylene substrates while preserving their valuable initial properties This unit has recently  upgraded  the Aixtron Black Magic Pro 4-inch System for the growth of graphene. It has also been purchased, installed and set-up by the unit parylene deposition device on flexible substrates. With this acquisition the unit will be able to offer high quality graphene grown in monolayer or multilayer CU sheets, as well as graphene transferred to different rigid and flexible parylen[...]

13 Jun

Update and improvement of unit 4 of NANBIOSIS

NANBIOSIS U4-Biodeposition and biosensing, led by Prof Laura Lechuga, has been recently updated and improved as a result of its participation in the project FICTS-1420-27 , selected by the MINECO for co-financing by the FEDER Program in ICTS 2014-2020. The Biodeposition has been updated with the ozone generation system with a new system (UV / Ozone Cleaner-Procleaner ™), with a lamp with improved power. In the case of the Biodetection unit,  the current device has been to updated in order to make it more competitive. Optical components that improve the performance of the instrument in reference to sensitivity have been changed, the fluidic[...]

12 Jun

New laboratory for unit 6 of NANBIOSIS

The equipment of NANBIOSIS U6-Processing of biomaterials and nanoestructuring, that at present are in several laboratories of the ICMAB-CSIC, are going to be transferred to their definitive location in the new laboratory of this NANBIOSIS unit. Given the large amount of equipment the process is expected to last two years, and itwill be done sequentially to continue to provide service to laboratory users. In this process, an engineer has been hired to play a key role, since he will not only be in charge of the transfer, but also to ensure the correct installation of equipment after its transfer and[...]

11 Jun

NANBIOSIS Unit 20 expands its equipments and capabilities

NANBIOSIS U20- In Vivo Experimental Platform, led by Dr Simó Schwartz and Dr. Ibane Ibasolo, has recently added new equipment as a result of its participation in the project FICTS1420-20, selected by the MINECO for co-financing by the FEDER Program in ICTS 2014-2020. The new equipment is a Coagulometer (Diagnostica Stago STart® 4 Hemostasis Analyzer) used for measuring the  plasma coagulation time upon incubation with different stimulators (PT, APTT, Fibrinogen, D-dimer (quantitative), Thrombin time, Reptilase time etc.) the use o f this equipment will  allow the Unit to test the hemocompatibility of novel nanomedicines in development.[...]

10 Jun

Evaluation of a New Design of Antireflux-Biodegradable Ureteral Stent in Animal Model

Francisco Miguel Sánchez Margallo, Assistant Director of NANBIOSIS and Scientific Director of JUMISC, is  co-authors of de article “Evaluation of a New Design of Antireflux-biodegradable Ureteral Stent in Animal Model” published by Urology. The research were carried out in the NANBIOSIS units in the JUMISC. The purpose was to determine the effects in urinary tract of a new antireflux-biodegradable ureteral stent. Thirty six ureters belonging to 24 pigs were used. The study began with endoscopic, nephrosonographic, and fluoroscopic assessments. Three study groups of ureters (n = 12) were then specified. In group I, a biodegradable antireflux ureteral stent (BDG-ARS) was inserted in the right ureter[...]

09 Jun

SINO-SPAIN Biomedical and Pharmaceutical Conference with NANBIOSIS participation

Last 7 June 2018 took place in Zaragoza, the Sino-Spain Biomedical and Pharmaceutical Conference, as a result of years of cooperation with Chinese institutions, organizad by Zaragoza University  and Aragonese Foundation for Research & Development of Aragon Government (ARAID), to promote initiatives and foster bilateral collaboration in biomedical and pharmaceutical sectors between Spain and China. The themes of the forum were: Molecular engineering for biomedical products Diagnoses &Design for new devices for medical uses Tissue Engineering and regenerative medicine Pharmacology and nanometerials for medical application Advanced therapies for cancer research   Researcher of three units of NANBIOSIS partcipated in the Conference: from U13. Tissue &am[...]

08 Jun

Photonic Label-Free Biosensors for Real-Time Analysis of Untreated Clinical and Environmental Samples

The biannual Conference on Bioanalytical Sensors will take place in June 24 – 29 in Newport,  US, with the theme “State-of-the-Art Bioanalytical Sensing Approaches for Healthcare and Therapeutics, Forensics, and Visualization of Living Systems”. Prof. Laura M. Lechuga, Scientific Director of NANBIOSIS  U4. Biodeposition and Biodetection Unit: is giving a Conference on “Photonic label-free biosensors for real-time analysis of untreated clinical and environmental samples” The focus of this meeting is on the development of new bioanalytical tools that provide highly specific and quantitative molecular data of biological systems leading to real applications to the clinic. Specific topics will include micro- and nanofluidics[...]